Screener
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Costs and expenses: | ||||
| Cost of revenue | 218 | 515 | 613 | 1,021 |
| Research and development | 18,066 | 11,449 | 33,723 | 23,033 |
| General and administrative | 6,048 | 5,386 | 12,791 | 11,525 |
| Licensing | 1,235 | 1,335 | 2,628 | 2,345 |
| Revaluation of contingent consideration | 300 | 1,500 | 300 | 1,800 |
| Total costs and expenses | 25,867 | 20,185 | 50,055 | 39,724 |
| Loss from operations | (24,238) | (18,408) | (46,430) | (36,492) |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's G&A?
- Aclaris Therapeutics (ACRS) reported G&A of $6.05M in Q2 2026.
- How has Aclaris Therapeutics's G&A changed year-over-year?
- Aclaris Therapeutics's G&A increased by 12.3% year-over-year, from $5.39M to $6.05M.
- What is the long-term trend for Aclaris Therapeutics's G&A?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's G&A has grown at a -1.8% compound annual growth rate (CAGR), from $23.62M to $21.97M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Aclaris Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude